Related Experiment Video

Updated: May 13, 2026

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies
09:01

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies

Published on: July 3, 2025

Links between Toll-like receptor 4 and breast cancer

Abubakr Ahmed1, H Paul Redmond, Jiang Huai Wang

  • 1Department of Academic Surgery; University College Cork (UCC); Cork University Hospital; Cork, Ireland.

Oncoimmunology
|March 26, 2013
PubMed

Insights

Toll-like receptor 4 (TLR4) activation promotes breast cancer growth. Targeting TLR4 offers a promising therapeutic strategy for breast cancer treatment, modulating immune responses against tumors.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Toll-like receptors (TLRs) are key in host defense and inflammation.
  • Recent research indicates TLR signaling pathways influence tumor progression.
  • Toll-like receptor 4 (TLR4) has emerged as a significant factor in cancer development.

Purpose of the Study:

  • To review the emerging links between TLR4 and breast cancer oncogenesis.
  • To discuss the potential of targeting TLR4 for breast cancer therapy.

Main Methods:

  • Literature review of recent studies on TLR4 and breast cancer.
  • Analysis of TLR-mediated signaling in tumor cell growth.
  • Exploration of therapeutic strategies targeting TLR4.

Main Results:

  • TLR4 activation supports tumor cell proliferation in vitro and in vivo.
  • TLR-mediated pathways contribute to breast cancer development.
  • Targeting TLR4 presents a novel therapeutic avenue.

Conclusions:

  • The role of TLR4 in breast cancer oncogenesis is increasingly recognized.
  • Targeting TLR4 holds promise for future breast cancer treatments.
  • Further research into TLR4 modulation is warranted for therapeutic development.
Keywords:
TLR4breast cancersignal transduction pathwaystumor progression and metastasis

More Related Videos

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling09:51

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which results in tumor...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...